Nektar Therapeutics (LTS:0UNL)
$ 1.0204 -0.01 (-0.97%) Market Cap: 188.15 Mil Enterprise Value: 51.91 Mil PE Ratio: 0 PB Ratio: 3.85 GF Score: 54/100

Q4 2023 Nektar Therapeutics Earnings Call Transcript

Mar 04, 2024 / 10:00PM GMT
Release Date Price: $0.905 (+16.91%)
Operator

Good day, and thank you for standing by, and welcome to the Nektar Therapeutics Fourth Quarter 2023 financial results conference call. (Operator Instructions) Once again, please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Vivian Wu. Please go ahead.

Vivian Wu
Nektar Therapeutics - Director, IR

Thank you, Crystal, and good afternoon, everyone. Thank you for joining us today. With us on the call are Howard Robin, our President and CEO; Dr. Jonathan Zalevsky, our Chief of Research and Development; Dr. Mary Tagliaferri, our Chief Medical Officer; Sandra Gardiner, our Chief Financial Officer; and Jennifer Ruddock, our Chief Business Officer.

On today's call, we expect to make forward-looking statements regarding our business, including statements regarding the therapeutic potential of future development candidates and programs. The timing of the initiation of clinical studies and the availability of clinical data for drug candidates, the timing and plans for future clinical data

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot